Science Publications

Sign Up
Sign In
Submit
Current Research in Public Health
Cite This Article Share Download PDF XML
  1. Home
  2. Journals
  3. Current Research in Public Health
  4. Archive
  5. Volume 3, Issue 1, 2024
  6. Article
Review Article Open Access March 13, 2024

Current Risk in the Supply Chain for the Active Pharmaceutical Ingredients Business

Sourav Adak 1,*
1
New Jersey, United States
Publihed in: Current Research in Public Health (Volume 3, Issue 1, 2024)
Page(s): 1-5
DOI: 10.31586/ujpp.2024.906
Received
January 20, 2024
Revised
February 28, 2024
Accepted
March 11, 2024
Published
March 13, 2024
Keywords
Active Pharmaceutical Ingredients; Supply chain; Generic Drugs; Business Intelligence System
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright: Copyright © The Author(s), 2024. Published by Scientific Publications
Article metrics
Views
1665
Downloads
247

Cite This Article

APA Style
Adak, S. (2024). Current Risk in the Supply Chain for the Active Pharmaceutical Ingredients Business. Current Research in Public Health, 3(1), 1-5. https://doi.org/10.31586/ujpp.2024.906
ACS Style
Adak, S. Current Risk in the Supply Chain for the Active Pharmaceutical Ingredients Business. Current Research in Public Health 2024 3(1), 1-5. https://doi.org/10.31586/ujpp.2024.906
Chicago/Turabian Style
Adak, Sourav. 2024. "Current Risk in the Supply Chain for the Active Pharmaceutical Ingredients Business". Current Research in Public Health 3, no. 1: 1-5. https://doi.org/10.31586/ujpp.2024.906
AMA Style
Adak S. Current Risk in the Supply Chain for the Active Pharmaceutical Ingredients Business. Current Research in Public Health. 2024; 3(1):1-5. https://doi.org/10.31586/ujpp.2024.906 
@Article{crph906,
AUTHOR = {Adak, Sourav},
TITLE = {Current Risk in the Supply Chain for the Active Pharmaceutical Ingredients Business},
JOURNAL = {Current Research in Public Health},
VOLUME = {3},
YEAR = {2024},
NUMBER = {1},
PAGES = {1-5},
URL = {https://www.scipublications.com/journal/index.php/UJPP/article/view/906},
ISSN = {2831-5162},
DOI = {10.31586/ujpp.2024.906},
ABSTRACT = {The active pharmaceutical ingredients (API) are very critical substances for generic drugs. Any issue in the global supply chain for sourcing APIs heavily impacts generic drugs demands in the market. It is imperative to keep a close eye on the API supply in order to spot possible priorities for domestic manufacturing as well as bottlenecks in the US pharmaceutical supply chain. Most of the API's are manufactured in countries like India and China, and any issue in the manufacturing or supply of the API's may critically impact generic drug production globally. The Government and regulatory agencies must take initiatives to mitigate the risk of supply chain interruptions in the API business.},
}
%0 Journal Article
%A Adak, Sourav
%D 2024
%J Current Research in Public Health

%@ 2831-5162
%V 3
%N 1
%P 1-5

%T Current Risk in the Supply Chain for the Active Pharmaceutical Ingredients Business
%M doi:10.31586/ujpp.2024.906
%U https://www.scipublications.com/journal/index.php/UJPP/article/view/906

TY  - JOUR
AU  - Adak, Sourav
TI  - Current Risk in the Supply Chain for the Active Pharmaceutical Ingredients Business
T2  - Current Research in Public Health
PY  - 2024
VL  - 3
IS  - 1
SN  - 2831-5162
SP  - 1
EP  - 5
UR  - https://www.scipublications.com/journal/index.php/UJPP/article/view/906
AB  - The active pharmaceutical ingredients (API) are very critical substances for generic drugs. Any issue in the global supply chain for sourcing APIs heavily impacts generic drugs demands in the market. It is imperative to keep a close eye on the API supply in order to spot possible priorities for domestic manufacturing as well as bottlenecks in the US pharmaceutical supply chain. Most of the API's are manufactured in countries like India and China, and any issue in the manufacturing or supply of the API's may critically impact generic drug production globally. The Government and regulatory agencies must take initiatives to mitigate the risk of supply chain interruptions in the API business.
DO  - Current Risk in the Supply Chain for the Active Pharmaceutical Ingredients Business
TI  - 10.31586/ujpp.2024.906
ER  -